



## Sosei Announces a New Appointment to its Board of Directors

Tokyo – 31 May 2010 – Sosei Group Corporation (“Sosei”; TSE, Mothers Index: 4565), a biopharmaceutical company, is pleased to announce a new appointment to its Board of Directors subject to the approval of the shareholders at the Annual General Meeting on 22 June.

### New Non-executive Director – Peter Bains

Mr Peter Bains served as a Senior Vice President of GlaxoSmithKline. In total, Peter’s career in GSK spanned over 20 years in various management positions. During his time there, he gained experience of marketing strategy development focusing primarily on the Asian market. He was also responsible for supporting the GlaxoWellcome and SmithKline Beecham merger, as well as organizational design for the post merger business. Sosei hopes to further enhance its business development by applying Peter’s knowledge and experience to the company management.

In addition to the above, President and CEO Shinichi Tamura, and Non-executive Directors Takuya Fujii, Isao Muramatsu, and Dr. Declan Doogan have been recommended for re-appointment to the board.

- Ends -

### Enquiries:

Sosei Group Corporation	
Tokyo Office	London Office
Hidetoshi TORAMI Executive Officer and CFO	Yumi YAMAMOTO Vice President, IR and Finance
+81-(0)3-5210-3399	+44-(0)20-7691-2081
<a href="mailto:htorami@sosei.com">htorami@sosei.com</a>	<a href="mailto:yyamamoto@sosei.com">yyamamoto@sosei.com</a>

### About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into Japan through exploitation of its unique position within global markets. For further information about Sosei, please visit [www.sosei.com](http://www.sosei.com).